Svetlana Nikic, Founder of Precision Oncology Consulting, shared a post on LinkedIn:
“Only a minority of new oncology diagnostics achieve rapid, reimbursed uptake in Europe due to fragmented HTA processes and heterogeneous reimbursement pathways, that collectively slow market access.
This is why I’m incredibly excited to host another live webinar titled ‘Healthcare Fragmentation in Europe: What It Means for Diagnostics and Precision Oncology,’ focusing on the complexities of European healthcare systems and reimbursement processes for diagnostic innovations.
Why is this important?
Well, the fragmented nature of European healthcare does not only create significant challenge for diagnostic companies seeking market access but it also delays the actual adoption of precision oncology by impacting the uptake of innovative therapies and, most critically, affect cancer patients’ quality of life and treatment outcomes.
I’m thrilled to have four exceptional individuals joining me to discuss these important topics, representing perspectives from early-stage cancer startups to well-established diagnostics and pharma providers. Their diverse experiences will provide comprehensive insights into navigating these challenges, and we’ll also discuss potential solutions.
Please join me and these incredible four individuals on October 29th at 5pm CET.
Tommi Lehtonen, Co-Founder and CEO of Hedera Dx
Prithwish Pal, PhD, MBA, Director of Global Product Marketing at Bio-Rad Laboratories,
Lee-Anne Zinetti, Executive Director, Precision Medicine Strategy – Oncology Portfolio at Novartis and
Benjamin Gannon, Vice President Europe and Americas at Guardant Health
If you find this discussion relevant to your work in oncology diagnostics and market access please share.”
More from Svetlana Nikic on OncoDaily.